GlobeNewswire Inc.··Bioage Labs, Inc.BioAge's BGE-102 Shows Best-in-Class Inflammation Reduction in Phase 1 Trial
BioAge's BGE-102 achieves best-in-class hsCRP reductions of ≥85% in Phase 1, with excellent tolerability. Phase 2 cardiovascular and diabetic macular edema trials planned for mid-2026.
BIOAPhase 1 clinical trialdiabetic macular edema